CancerDrs

Ovarian Cancer clinical trials in Illinois

58 actively recruiting ovarian cancer trials at 75 sites across Illinois.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Illinois:
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Rush-Copley Medical Center — Aurora, Illinois
  • Advocate Outpatient Center - Aurora — Aurora, Illinois
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • OSF Saint Joseph Medical Center — Bloomington, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Illinois:
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Rush-Copley Medical Center — Aurora, Illinois
  • Advocate Outpatient Center - Aurora — Aurora, Illinois
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • Carle BroMenn Outpatient Center — Bloomington, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Illinois:
  • Rush-Copley Medical Center — Aurora, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • Memorial Hospital of Carbondale — Carbondale, Illinois
  • SIH Cancer Institute — Carterville, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Illinois:
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Rush-Copley Medical Center — Aurora, Illinois
  • Saint Mary's Hospital — Centralia, Illinois
  • Lurie Children's Hospital-Chicago — Chicago, Illinois
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…

Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Illinois:
  • Illinois Cancer Specialists — Arlington Heights, Illinois
  • Northwestern Memorial Hospital — Chicago, Illinois
  • Rush University Medical Center — Chicago, Illinois
  • The University of Chicago Medicine — Chicago, Illinois
  • OSF Saint Fracis Medical Center — Peoria, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Illinois:
  • Carle Cancer Center — Effingham, Illinois
  • Northshore University Health System-Evanston Hospital — Evanston, Illinois
  • City of Hope - Chicago Cancer Center — Zion, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…

Sponsor: AstraZeneca
NCT ID: NCT07218809
Sites in Illinois:
  • Research Site — Chicago, Illinois
  • Research Site — Evanston, Illinois
  • Research Site — Peoria, Illinois
  • Research Site — Urbana, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Illinois:
  • NorthShore University HealthSystem — Evanston, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard ca…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07318558
Sites in Illinois:
  • Illinois Cancer Specialists (ICS) ( Site 8009) — Arlington Heights, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Illinois:
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • SIH Cancer Institute — Carterville, Illinois
  • Illinois CancerCare-Carthage — Carthage, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Illinois:
  • University of Illinois — Chicago, Illinois
  • Carle at The Riverfront — Danville, Illinois
  • Carle Physician Group-Effingham — Effingham, Illinois
  • Carle Physician Group-Mattoon/Charleston — Mattoon, Illinois
  • Carle BroMenn Medical Center — Normal, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…

Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Illinois:
  • Rush Md Anderson Cancer Center /ID# 274926 — Chicago, Illinois
  • OSF St. Francis Medical Center /ID# 274752 — Peoria, Illinois
  • Carle Foundation Hospital /ID# 276470 — Urbana, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Illinois:
  • Site 0324 - Illinois Cancer Specialists — Niles, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Illinois:
  • Hope and Healing Cancer Services — Hinsdale, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …

Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Illinois:
  • Northwestern Memorial Hospital — Chicago, Illinois
  • Ascension Illinois-Skokie Infustion Center — Skokie, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Illinois:
  • Lurie Children's Hospital-Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the st…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06787612
Sites in Illinois:
  • University of Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Illinois:
  • Orchard Healthcare Research Inc — Skokie, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The ma…

Sponsor: Compugen Ltd
NCT ID: NCT06888921
Sites in Illinois:
  • The University of Chicago Medical Center — Chicago, Illinois
  • Northwestern Memorial Hospital — Warrenville, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…

Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Illinois:
  • University of Chicago Medical Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT04590326
Sites in Illinois:
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois
  • University of Chicago Medical Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…

Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Illinois:
  • University of Illinois Cancer Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESA…

Sponsor: GlaxoSmithKline
NCT ID: NCT04641247
Sites in Illinois:
  • GSK Investigational Site — Harvey, Illinois
View on ClinicalTrials.gov →

Showing 25 of 58 trials with sites in Illinois. See all ovarian cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10